Out Of The Pipeline

Trazodone extended release for major depressive disorder

Current Psychiatry. 2010 December;9(12):76-84

References

1. Oleptro [package insert]. Dublin, Ireland: Labopharm Europe Limited; 2010.

2. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003;43(4):414-422.

3. Beasley CM, Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52:294-299.

4. Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomized double blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21:1139-1146.

5. Munizza C, Olivieri L, Di Loreto G, et al. A comparative, randomized double blind study of trazodone prolonged-release and sertraline in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2006;22:1703-1713.

6. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Pyschopharmacol. 1994;14:99-106.

7. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone in the treatment of major depression. J Clin Psychopharmacol. 1994;14:170-179.

8. Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry. 1980;41:250-255.

9. Rickels K, Case WG. Trazodone in depressed outpatients. Am J Psychiatry. 1982;139:803-806.

10. Perry PJ, Garvey MJ, Kelly MW, et al. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry. 1989;50:290-294.

11. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont). 2009;6(5):20-33.

12. Sheehan DV, Rozova A, Gossen ER, et al. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5-22.

13. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.

14. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry. 2005;66(1):100-106.

15. Thompson JW, Jr, Ware MR, Blashfield RK. Psychotropic medications and priapism: a comprehensive review. J Clin Psychiatry. 1990;51:430-433.

Dr. Sheehan has received grant funding support from, been affiliated with, or received honoraria and travel expenses related to lectures/presentations or consultant activities from the following organizations: Abbott Laboratories,^1,2,3 Ad Hoc Committee, Treatment Drug and Assessment Research Review,¹ Alexza,¹ Alza Pharmaceuticals, Palo Alto, CA,¹ the American Medical Association,² American Psychiatric Association Task Force on Benzodiazepine Dependency,¹ American Psychiatric Association Task Force on Treatments of Psychiatric Disorders,¹ American Psychiatric Association Working Group to Revise DSM III Anxiety Disorders Section,¹ Anclote Foundation,² Anxiety Disorders Resource Center,¹ Anxiety Drug Efficacy Case, the FDA,¹ Applied Health Outcomes/Xcenda,¹ AstraZeneca,^1,2,3 Avera Pharmaceuticals,^1,2 Boehringer Ingelheim,³ Boots Pharmaceuticals,³ Bristol-Myers Squibb,^1,2,3 Burroughs Wellcome,^2,3 Cephalon,¹ Charter Hospitals,³ Ciba Geigy,³ Committee (RRC) of the National Institute for Mental Health on Anxiety and Phobic Disorder Projects,¹ Connecticut and Ohio Academies of Family Physicians,¹ Cortex Pharmaceutical,¹ Council on Anxiety Disorders,¹ CPC Coliseum Medical Center,¹ Cypress Bioscience,¹ Dista Products Company,³ Division of Drugs and Technology, American Medical Association,¹ Eisai,^1,2 Eli Lilly and Company,^2,3 Excerpta Medica Asia,³ Faxmed, Inc.,¹ Forest Laboratories,^1,2 Glaxo Pharmaceuticals,³ GlaxoSmithKline,^1,2,3 Glaxo-Wellcome,² Hospital Corporation of America,³ Humana,³ ICI,³ INC Research,¹ International Clinical Research (ICR),² International Society for CNS Drug Development (ISCDD),¹ Janssen Pharmaceuticals,^1,2,3 Jazz Pharmaceuticals,^1,2 Kali-Duphar,^2,3 Labopharm,¹ Layton Bioscience,¹ Lilly Research Laboratories,¹ Lundbeck, Denmark,¹ Marion Merrell Dow,³ McNeil Pharmaceuticals,³ Mead Johnson,^2,3 Medical Outcome Systems,⁴ MediciNova,^1,2 Merck Sharp & Dohme,^2,3 National Anxiety Awareness Program,¹ National Anxiety Foundation,¹ National Depressive and Manic Depressive Association,¹ National Institute on Drug Abuse,² National Institute of Health,² Neuronetics,¹ Novartis Pharmaceuticals Corp.,² Novo Nordisk,³ Organon,^1,3 Orion Pharma,¹ Parexel International Corporation,¹ Parke-Davis,^2,3 Pfizer, Inc.,^1,2,3 Pharmacia,¹ Pharmacia and Upjohn,^1,3 Philadelphia College of Pharmacy and Science,¹ Pierre Fabre, France,¹ Quintiles,² Rhone Laboratories,³ Rhone-Poulenc Rorer Pharmaceuticals,³ Roche,¹ Roerig,³ Sandoz Pharmaceuticals,^2,3 sanofi-aventis,^1,2,3 Sanofi-Synthelabo Recherche,^1,2 Schering Corporation,³ Sepracor,¹ Shire Laboratories, Inc.,¹ SmithKline Beecham,^1,2,3 Solvay Pharmaceuticals,^1,3 Takeda Pharmaceuticals,¹ Tampa General Hospital,¹ University of South Florida Psychiatry Center,² University of South Florida College of Medicine, TAP Pharmaceuticals,^2,3 Targacept,¹ Tampa General Hospital-University Psychiatry Center,³ Tikvah Therapeutics,¹ Titan Pharmaceuticals,¹ United Bioscience,² The Upjohn Company,^1,2,3 U.S. Congress-House of Representatives Committee,¹ University of South Florida Friends of Research in Psychiatry, Board of Trustees,¹ Warner Chilcott,^2,3 World Health Organization,¹ Worldwide Clinical Trials,² Wyeth-Ayerst,^1,2,3 ZARS,¹ and Zeneca Pharmaceuticals.1

1: Consultant; 2: Grant/Research Support; 3: Lectures/ Presentations; 4: Stock Holder